| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRM4 |
| Uniprot No | P08173 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-479aa |
| 氨基酸序列 | MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVNRQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTVPDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAKTLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGSATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIVPATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMVLVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRM4重组蛋白的3篇参考文献示例(注：文献为虚构，仅用于示例格式)：
1. **"Functional Expression and Characterization of Recombinant Human CHRM4 in HEK293 Cells"**
*作者：Zhang Y, et al.*
*摘要*：本研究成功在HEK293细胞中表达了重组人源CHRM4蛋白，并通过放射性配体结合实验验证其与毒蕈碱拮抗剂的结合活性，证实其功能与天然受体一致。
2. **"Structural Insights into CHRM4 Receptor Activation Using Cryo-EM"**
*作者：Thompson RL, et al.*
*摘要*：通过冷冻电镜技术解析了重组CHRM4与G蛋白复合物的三维结构，揭示了其激活状态下与下游信号蛋白的相互作用机制。
3. **"Optimization of CHRM4 Recombinant Protein Production in Baculovirus Expression Systems"**
*作者：Kumar S, et al.*
*摘要*：优化了杆状病毒-昆虫细胞表达系统中CHRM4重组蛋白的产量和纯度，为大规模药物筛选提供了高稳定性蛋白样本。
4. **"CHRM4 Allosteric Modulation Screened via Recombinant BRET Assays"**
*作者：Garcia M, et al.*
*摘要*：利用基于重组CHRM4的BRET(生物发光共振能量转移)技术，筛选出新型变构调节剂，为神经精神疾病治疗提供潜在候选分子。
(注：以上文献及作者为模拟生成，实际引用时需查询真实数据库如PubMed、Google Scholar。)
**Background of CHRM4 Recombinant Protein**
The **CHRM4 (Cholinergic Receptor Muscarinic 4)** recombinant protein is a engineered form of the human M4 muscarinic acetylcholine receptor, a member of the G protein-coupled receptor (GPCR) superfamily. CHRM4 is one of five muscarinic receptor subtypes (M1-M5) that mediate the parasympathetic nervous system's responses to acetylcholine, playing critical roles in modulating neuronal signaling, smooth muscle contraction, and glandular secretion.
CHRM4 is predominantly expressed in the central nervous system (CNS), particularly in regions like the striatum, hippocampus, and cortex, where it regulates cognitive functions, motor control, and dopaminergic signaling. It couples primarily to inhibitory Gαi/o proteins, reducing cyclic AMP (cAMP) levels and modulating ion channel activity. Dysregulation of CHRM4 has been implicated in neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and drug addiction, making it a target for therapeutic intervention.
Recombinant CHRM4 proteins are produced using heterologous expression systems (e.g., HEK293 or insect cells) to ensure proper post-translational modifications and membrane localization. These proteins often include tags (e.g., GFP, His-tag) for purification, detection, or functional studies. They enable detailed studies of receptor-ligand interactions, signaling mechanisms, and structure-function relationships. Additionally, CHRM4 recombinant proteins are critical tools in drug discovery, particularly for identifying selective agonists, antagonists, or allosteric modulators that could normalize receptor activity in disease states.
Recent research highlights CHRM4's role as a potential target for treating cognitive deficits and movement disorders, with efforts focused on developing subtype-selective ligands to minimize off-target effects associated with broader muscarinic modulation.
×
